Latest Product Launch News

Little Green Pharma reports a robust 75% revenue increase to $9.5 million for December quarter, driven by strong European market growth and strategic product launches.

BirdDog Technology reports a strategic pivot with four next-generation product launches, a 20% price increase, and a robust cash position, despite a 13% revenue decline in H1 FY25.

EVE Health Group has completed the sale of its Robyndale tea tree property and relaunched its postbiotic concentrate range, signaling a strategic shift towards innovation and growth in the Australian market.

Terragen Holdings reports robust quarterly progress, highlighted by successful beef feedlot trials and a $4.76 million equity raise, setting the stage for its new probiotic product launch in March 2025.

FirstWave Cloud Technology reports a cashflow positive first half of FY25, driven by strategic contract renewals and new technology launches, despite a slight decline in recurring revenue due to customer churn.

Acrux Limited has launched its Nitroglycerin 0.4% Ointment and successfully raised nearly $4 million, positioning the specialty pharma company for sustained revenue growth.

Credit Corp Group has reported a robust 32% rise in underlying NPAT for H1 FY2025, driven by strong US collections and consumer lending growth, while reaffirming its full-year guidance and announcing a healthy interim dividend.

Beforepay Group has reported a strong Q2 FY25 with record revenue exceeding $10 million and a growing active user base, while introducing its new Personal Loan product.

Articore Group reveals a strategic restructure delivering significant cost savings and improved margins, even as marketplace revenue continues to decline. The launch of a new product, Dashery, aims to diversify revenue streams.

Audeara Ltd reports a 70% jump in Q2 FY25 cash receipts, driven by new product launches and a major contract with Avedis Zildjian. The company’s expansion into Taiwan and international markets signals a promising growth trajectory.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.

Starpharma reports encouraging FDA feedback on its DEP® SN38 candidate for ovarian cancer and prepares for product launches in Saudi Arabia and UAE, supported by a solid $20.3 million cash position.